Maze Therapeutics Inc（MAZE）财务数据MAZEMaze Therapeutics Inc

Evaluating the bottom line, Maze Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -372.94%, while the net margin is -344.68%. These profitability ratios, combined with a Return on Equity (ROE) of -37.35%, provide a clear picture of how effectively MAZE converts its operational activities into shareholder value.

In the context of the broader market, MAZE competes directly with industry leaders such as PAHC and LTGO. With a market capitalization of $1.51B, it holds a significant position in the sector. When comparing efficiency, MAZE's gross margin of 100.00% stands against PAHC's 31.73% and LTGO's N/A. Such benchmarking helps identify whether Maze Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Maze Therapeutics reported a gross margin of 100% in Q1 and Q2 of 2026, indicating strong potential for profitability once revenue streams stabilize. However, the company has been experiencing significant net losses, with a net income loss of $44.7 million in Q2 2026, which raises concerns about its financial sustainability in the short term.